Form 4: C4 Therapeutics Executive Mark Mossler Reports Acquisition of Shares and Stock Options

Mark Mossler, Chief Accounting Officer of C4 Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• On February 14, 2024, Mark Mossler, the Chief Accounting Officer of C4 Therapeutics, acquired 18,290 restricted stock units (RSUs) and 27,430 stock options.
• The RSUs vest in four equal annual installments starting February 14, 2025.
• The stock options vest in sixteen equal quarterly installments starting May 14, 2024, and have an exercise price of $7.31.
• Following these transactions, Mossler directly owns 19,790 shares of C4 Therapeutics common stock, which includes 1,500 shares inadvertently omitted from a previous filing.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting required information about stock transactions. The sentiment is neither particularly positive nor negative.

Positives

• The acquisition of RSUs and stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules of the RSUs and stock options suggest a multi-year horizon for potential value realization.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders, as they provide insight into executive compensation and ownership.

Key Dates